Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
Conclusion:
In a Brazilian subpopulation of patients with RA, tofacitinib reduced disease signs and symptoms and improved physical function up to Month 24, with a safety profile consistent with findings from global studies.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
More News: Arthritis | Brazil Health | Clinical Trials | Disability | Internal Medicine | Methotrexate | Pain | Rheumatoid Arthritis | Rheumatology | Study | Tuberculosis